Our industry sees debilitating challenges due to the limitations of traditional trial models in terms of responsiveness and efficiency, specifically in regard to fragmentation among the various technologies and vendors utilized to achieve a common goal – a successful clinical trial. There are a lot of moving parts that occur at all stages of a clinical trial where data is being captured across numerous different platforms or cross-functional teams are executing study tasks independently one of another, ultimately hindering study progress and running up additional unwanted costs. By adopting a unified internal platform to manage study activities and data collection, we can overcome these bottlenecks by streamlining operations and providing better control over the interdependent efforts required to conduct a clinical trial smoothly and on-time.
In this fireside chat, Lindus Health and Signos Chief of Staff, Dan Gusz, reflect on the barriers sponsors have faced for years as a result of fragmentation, as well as how their studies can drastically improve when managed within a singular software environment.
Tune in to discover how modern CROs like Lindus Health employ a unified tech stack designed for running clinical studies end-to-end with speed, quality and patient experience in mind.
Dr. Paul Billings Joins Lindus Health's Scientific Advisory Board
Lindus Health has announced the appointment of Dr. Paul Billings to its Scientific Advisory Board, strengthening its expertise in diagnostic and genomic medicine. A recognized leader in diagnostics with decades of experience across industry and clinical research, Dr. Billings will help guide Lindus Health’s strategy for designing and executing high-quality diagnostic clinical trials, supporting faster, more reliable paths from diagnostic innovation to patient impact.
Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials
This collaboration is essential to eliminating traditional barriers in patient recruitment and reducing friction when transitioning between development stages and CRO partners, ultimately accelerating the delivery of breakthrough treatments to patients.
